VeriSilicon and Innobase Collaboratively Launched Second-Generation Yunbao Series 5G RedCap/4G LTE Dual-Mode Modem IP
23.1.2025 01:00:00 CET | Business Wire | Press release
Advancing cellular mobile communication technology innovation and accelerating the lightweight 5G application adoption
VeriSilicon (688521.SH) today announced the joint launch of the second-generation Yunbao series 5G RedCap/4G LTE dual-mode modem IP, Yunbao 2, in collaboration with Innobase, a wireless communication technology and chip provider. This new modem IP has successfully completed production validation.
The newly launched modem IP integrates and reuses 4G and 5G hardware accelerators, delivering industry-leading performance in terms of area and power consumption. This IP complies with the 3GPP 5G Rel-17 standard and supports both 5G RedCap and 4G LTE FDD/TDD, achieving uplink and downlink transmission rates of 170 Mbps and 120 Mbps, respectively. It also supports multi-SIM standby and features key 5G capabilities such as Ultra-Reliable Low Latency Communication (URLLC), 5G LAN, and network slicing. Furthermore, chips developed using the Yunbao 2 modem IP can be paired with Innobase’s production-validated high-performance dual-mode RF chips, enabling seamless product-level integration and significantly accelerating the commercialization process for customers.
Under the guidance and organization of the IMT-2020 (5G) Promotion Group, the Yunbao series has successfully completed 5G RedCap terminal equipment and field performance testing with Nokia Shanghai Bell and ZTE. Additionally, it has completed interoperation tests between 5G RedCap terminals and base stations in collaboration with partners. These tests were conducted strictly adhering to the standards set by the Promotion Group, covering the full range of 5G RedCap terminal functionalities and performance metrics. The results thoroughly validated the overall capabilities of the Yunbao series, as well as its seamless interoperability with multiple network equipment vendors.
“The commercialization of RedCap in China has entered a rapid growth phase. As a new 5G variant defined under the 3GPP Rel-17 standard, RedCap features low cost, low latency, private network, and efficient spectrum utilization, making it an ideal solution for wearable devices, industrial IoT, and mass-market smartphones,” said Lu Wenbo, Senior Vice President of Innobase. “Innobase has introduced a variety of mass-production-ready products, including 5G IoT modules, MiFi devices, and mass-market 5G smartphones, which have successfully validated the Yunbao series IP at the product level. In the future, Innobase will leverage its extensive expertise in cellular communication technologies to develop the Yunbao X series featuring ultra-low-cost and ultra-low-power designs, to address the needs of consumer electronics and IoT applications. With the RedCap market rapidly evolving, we are excited to collaborate with VeriSilicon to deliver more advanced 5G multi-mode modem IP solutions to our customers.”
“The cost and performance of 5G RedCap chips are comparable to those of 4G, further expanding the boundaries of existing 4G application scenarios,” said Wiseway Wang, Executive Vice President, General Manager of Custom Silicon Platform Division of VeriSilicon. “Through our collaboration with Innobase, VeriSilicon is able to offer production-validated 4G/5G RedCap dual-mode IPs, further strengthening our existing IP ecosystem. VeriSilicon remains committed to driving innovation in low-power, high-performance wireless communication technologies, providing comprehensive wireless communication solutions, including RF, baseband, and protocol stacks, for IoT applications. Looking ahead, VeriSilicon will continue working closely with industry partners to build a global cellular communication ecosystem and contribute to an intelligent, connected future.”
About Innobase
Innobase is a leading fabless chip design company for cellular mobile communications. It designs chipset of 4G/5G and future 6G, including Baseband, RF, and PMIC for mobile terminals. Its dual mode chipset of 4G LTE/5G RedCap is commercialized with customers including telecom operators, IoT module makers, and mobile phone IDHs/ODMs. For more information, please visit: www.innobase.com.cn
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250121582002/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom